Physician profile
Bryan J Kozinski
NPI 1265427553
$10,200.15
in general payments reported to CMS, 2019-2025
57 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,039 · 2020: $978 · 2021: $658 · 2022: $1,255 · 2023: $1,693 · 2024: $1,928 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,269.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,250.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $988.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $823.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $813.39 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $694.98 | 2021-2025 | |
| Pfizer INC. | $576.78 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.83 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Lilly USA, LLC | $397.98 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $363.88 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $361.04 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $339.53 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $247.12 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $233.45 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.03 | 2019-2024 | Trintellix |
| Novartis Pharmaceuticals Corporation | $225.99 | 2022-2025 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Kozinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.